Pfizer says obesity injection shows promise as monthly treatment in mid-stage trial
The data on Pfizer's GLP-1 offer early evidence that the injection can be administered less frequently than existing drugs without sacrificing efficacy.
The data on Pfizer's GLP-1 offer early evidence that the injection can be administered less frequently than existing drugs without sacrificing efficacy.
What's Your Reaction?
Economist Admin
Admin managing news updates, RSS feed curation, and PR content publishing. Focused on timely, accurate, and impactful information delivery.
